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Abstract 
Background: In addition to the conventional opportunistic infections in solid organ transplantation (SOT) and 
hematopoietic stem cell transplantation (HSCT) recipients, cytomegalovirus (CMV) infection is associated with 
various chronic inflammatory diseases or poor outcomes in non-immunocompromised critically ill patients. To 
evaluate the burden or outcome of CMV replication in non-transplant individuals, we compared the incidence 
rates (IRs) for CMV disease and all-cause mortality between SOT recipients, HSCT recipients, and 
non-transplant population.  
Methods: The SOT (N=16,368) and HSCT (N=10,206) cohorts between 2010 and 2015 were established 
using the WHO ICD-10 from the whole population-based large database of the Health Insurance Review & 
Assessment Service (HIRA). CMV cases, defined as symptomatic disease with isolation of virus, DNA, pp65 
antigen, and pathology except CMV syndrome, were extracted with the unique codes for relief of medical costs 
of HIRA in the same dataset. Cox’s proportional hazard regression analyses and log-rank test in the Kaplan–
Meier curves were performed to compare all-cause mortality between the three groups.  
Results: The CMV IRs adjusted by age and sex were significantly higher in the SOT (adjusted IR [95% 
confidence intervals], 33.1 [28.8-38.0] per 1,000 person-years) and HSCT recipients (5.1 [4.6-6.1] per 1,000 
person-years) than in the whole population (0.58 [0.49-0.67] per 100,000 person-years). However, SOT 
recipients with CMV (18/283, 6.4%) had significantly lower all-cause mortality than non-transplant individuals 
with CMV (207/1,258, 16.5%) (adjusted hazard ratio [95% CI], 0.42 [0.25-0.67], log-rank P < 0.001).  
Conclusion: These data suggest that CMV disease in patients without transplants is associated with poor 
outcomes. 
Key words: Cytomegalovirus, Disease, Incidence, Mortality, Population, Solid organ transplantation, 
Hematopoietic stem cell transplantation 
Introduction 
The ubiquitous cytomegalovirus (CMV) can lead 
to diverse clinical outcomes through acute direct or 
chronic indirect pathogenesis in populations with 
different comorbidities [1-3]. In the era of growing 
aging population and immunomodulation drugs, 
CMV could exert an influence on public health in 
various ways, including chronic inflammatory 
vascular disorders besides tissue-invasive end-organ 
disease [1]. Recently, several studies have reported 
the association of CMV with neurocognitive function, 
metabolic diseases, stroke, myocardial infarction, 
autoimmune diseases, or frailty in addition to 
well-known conventional opportunistic infections in 
severely immunocompromised patients or congenital 
CMV infection [4-13]. The non-transplant, 
non-immunocompromised, critically ill patients in 
intensive care unit are another risk group, who have a 
higher rate of CMV reactivation on mortality 
(approximately 15-20% of incidence), even though it is 








causal relationship with life-threatening outcomes or 
represents the bystander effect by hyperactivation of 
immune system in severe diseases [14-17]. Taken 
together, the burden of potential CMV infection or 
disease caused by life-long periodic reactivation 
necessitates the development of CMV vaccine for 
widespread elimination [18-20]. 
Despite the clinical significance and impact, the 
precise incidence rate (IR) per person-years of CMV 
infection or disease in solid organ transplantation 
(SOT) or hematopoietic stem cell transplantation 
(HSCT) recipients as well as non-transplant 
individuals has not been evaluated [1]. Most studies 
assessing post-SOT CMV epidemiology presented 
only the frequency (percentage) of CMV infection or 
disease in a single institution with relatively small 
recipients (6.2-60%, 1-65%, 19-72.1%, and 15-33.9% in 
kidney, liver, heart, and pancreas transplantation, 
respectively) in clinical settings applying various 
preventive strategies against CMV [21-31]. Similarly, 
the overall incidence of CMV infection or disease after 
allo-HSCT was reported to range from 3% to 40% 
[32-37]. In addition, the definition of CMV infection or 
disease as well as the cut-off threshold for clinically 
significant DNAemia were not uniform in 
publications [21-23,27,28,30,32]. Some studies defined 
CMV infection as asymptomatic viremia, DNAemia, 
or antigenemia, while others used suspected or 
probable end-organ disease [22,23,32,38]. The most 
recent systemic review of real-world data in kidney 
transplant recipients showed that the estimated 
pooled incidences of CMV infection, including acute 
viral syndrome or end-organ disease, were quite 
heterogeneous according to the various risk factors, 
severity of immunosuppression, or methods of CMV 
prevention, including the dosage of anti-CMV agents 
[39].  
The association between CMV and various 
comorbidities or mortality in general population has 
been evaluated previously using CMV seropositivity 
rates or immunoglobulin G (IgG) concentrations, but 
do not demonstrate the presence of virus in the host 
body as shown by methods, such as the measurement 
of CMV DNA, virion, or pp65 antigen [12,13,40-43]. 
However, the clear definition of CMV disease should 
be based on virus isolation by culture, nucleic acid 
amplification, or protein tests [30,44]. The result of 
CMV IgG concentration may represent the past 
exposure history and/or the current status of humoral 
immunity, but does not indicate active lytic CMV 
replication [30,44,45].  
Therefore, we assessed the difference in IRs for 
CMV per person-years between SOT recipients, HSCT 
recipients, and non-transplant individuals and the 
effect of CMV end-organ disease except CMV 
syndrome on all-cause mortality in these groups to 
evaluate the clinical impact and burden of active CMV 
replication, defined as CMV detection by polymerase 
chain reaction, culture, shell viral assay, antigen test, 
or histopathology, using a general population-based 
large cohort dataset.  
Materials and methods 
Cohort construction and data extraction 
The Korean National Health Insurance System 
(NHIS) organized by the government provides a 
single healthcare insurance service to the entire 
nation, covering approximately 50 million people. The 
Health Insurance Review & Assessment Service 
(HIRA), managed by the NHIS, establishes the whole 
database consisting of general information, diagnosis, 
drug, and healthcare services subset to operate the 
efficient claim process to healthcare providers [46]. 
Using the nationwide database warehouse in the 
HIRA, we constructed SOT and HSCT recipient 
cohorts who received transplantation between 
January 2010 and December 2015. For the retrieval of 
recipients, we used the unique HIRA codes (V084, 
V085, V086, V087, V088 for SOT, and V081, V082, 
V083 for HSCT) to identify the rare incurable diseases 
for the direct relief co-payment policy [47], which are 
perfectly matched with the International Statistical 
Classification of Disease and Related Health Problems 
10th Revision (ICD-10) codes version 2016 by the 
World Health Organization (Z94.0, Z94.1, Z.94.2, 
Z.94.3, Z.94.4, and Z94.8) [48]. The SOT and HSCT 
cohorts for 6 years included 16,368 and 10,206 
recipients, respectively. 
 The HIRA includes CMV disease except CMV 
syndrome as rare incurable diseases and manages a 
strict review process for the relief of medical costs 
[47]. For application of the unique code V104 for CMV 
disease except CMV syndrome, physicians should 
submit the results of CMV detection in blood, body 
fluid, or tissues using histopathologic findings, 
nucleic amplification test of polymerase chain 
reaction, pp65 antigen test, virus culture, and shell 
viral assay to the HIRA. The definition of CMV 
disease in the HIRA process is matched by the ICD-10 
codes of B25 (cytomegaloviral disease), B25.0 
(cytomegaloviral pneumonitis), B25.1 (cytomega-
loviral hepatitis), B25.2 (cytomegaloviral pancreatitis), 
B25.8 (other cytomegaloviral diseases), and B25.9 
(cytomegaloviral disease, unspecified), and does not 
include the P35.1 (congenital CMV infection) or B27.1 
(cytomegaloviral mononucleosis) [48]. The asympto-
matic CMV isolation as CMV viremia, DNAemia, and 
pp65 antigenemia in the regular screening or 
surveillance for post-transplant CMV prevention is 




not acceptable to submission for the HIRA review. We 
used the term ‘CMV cases’ in this study, defined as 
CMV disease except CMV syndrome [30,44].  
The co-morbid diseases were identified by 
ICD-10 codes: (1) type 2 diabetes mellitus (DM) (E11), 
(2) end stage renal disease (ESRD) on dialysis (N18.5), 
(3) chronic heart diseases including congestive heart 
failure (CHF) (I50.0), left ventricular failure (I50.1), 
heart failure, unspecified (I50.9), myocardial 
infarction (I21, I22, I25.2), hypertensive heart disease 
with CHF (I11.0), and cardiomyopathy (I42, I25.5), (4) 
chronic liver diseases including hepatic failure (K72, 
K70.4), chronic viral hepatitis (B18.0, B18.1, B18.2, 
B18.8, B18.9), and liver cirrhosis (K74, K70.3), (5) 
chronic lung diseases including chronic obstructive 
pulmonary diseases (J44), chronic emphysema (J43.8, 
J43.9), and interstitial lung diseases (J84), (6) human 
immunodeficiency virus-1 (HIV-1) infection (B20-B24, 
Z21). 
This study was approved by the NHIS and the 
Gangnam Severance Institutional Review Board, and 
informed consent was waived because of the 
anonymous data (Study No: REQ0000017664 and IRB 
No: 3-2017-0341). 
Statistical analyses 
 The data are expressed as numbers (percentage) 
or means ± standard deviations, as well as IRs or 
hazard ratios (HRs) (95% confidence intervals [CI]). 
The standardized IRs and HRs per person-years were 
obtained by adjusting for age and sex using the 2010 
South Korea Population and Housing Census data. 
We used the ANOVA and chi-square test to compare 
the continuous and nominal variables, respectively, 
between the three groups. Cox proportional hazards 
regression analysis was performed to compare the 
mortality rates between SOT recipients, HSCT 
recipients, and non-transplant individuals. Kaplan–
Meier curves were constructed to compare the 
incidence probability of CMV cases or all-cause death. 
All statistical analyses were performed using SAS 
software (version 9.1; SAS Institute, Cary, NC, USA), 
and a two-tailed P-value of < 0.05, was considered 
statistically significant. 
Results 
Incidence rates of CMV cases in SOT and 
HSCT recipients 
 The percentages of patients with CMV cases 
were 0.003%, 1.7%, and 0.44% in non-transplant 
individuals, SOT recipients, and HSCT recipients, 
respectively. The adjusted IR of CMV in the 
whole-population cohort, including 50 million 
individuals per year between 2010 and 2015 was 
0.58/100,000 person-years (Table 1). The SOT 
(adjusted IR [95% CI], 33.1 [28.8-38.0] per 1,000 
person-years) and HSCT recipients (5.1 [4.6-6.1] per 
1,000 person-years) had significantly higher IRs than 
that in the whole population (5,517- and 850-fold, 
respectively). In the SOT cohort, the liver transplant 
recipients had the lowest IR (11.1 [7.7-16.3] per 1,000 
person-years). The IR of CMV in heart transplant 
recipients (104.2 [66.4-163.7] per 1,000 person-years) 
was the highest, followed by multi-organ (72.7 
[30.2-175.4]) and kidney transplantation (44.3 
[37.7-52.1] per 1,000 person-years) with 8.6, 6.3, and 
3.8, respectively, compared to liver transplantation. 
The lung transplant recipients had a relatively low IR 




Figure 1. Difference in incidence probability for development of CMV disease except CMV syndrome according to the transplant organ in solid organ transplantation recipients 




Table 1. Incidence of CMV disease except CMV syndrome in solid organ and hematopoietic stem cell transplantation recipients 
Populations Year 
2010 2011 2012 2013 2014 2015 
SOT        
Total Total Pop. 2,360 2,858 3,072 2,971 3,142 3,411 
CMV casesa 31 25 45 60 69 53 
Crude IRb 1.31 (0.85-1.77) 0.87 (0.53-1.22) 1.46 (1.04-1.89) 2.02 (1.51-2.53) 2.20 (1.68-2.71) 1.55 (1.14-1.97) 
Std. IRb 1.34 (0.67-2.01) 1.02 (0.39-1.64) 2.07 (1.07-3.07) 2.97 (1.76-4.17) 3.16 (2.05-4.26) 2.14 (1.26-3.01) 
Kidney Total Pop. 1,258 1,604 1,741 1,716 1,775 1,875 
CMV casesa 24 19 36 41 42 35 
Crude IRb 1.91 (1.15-2.66) 1.18 (0.65-1.71) 2.07 (1.40-2.74) 2.39 (1.67-3.11) 2.37 (1.66-3.07) 1.87 (1.25-2.48) 
Std. IRb 1.71 (0.86-2.55) 1.19 (0.37-2.01) 2.44 (1.14-3.73) 7.63 (0-17.08) 2.86 (0.95-4.78) 2.43 (0.51-4.35) 
Liver Total Pop. 1,012 1,131 1,191 1,084 1,181 1,307 
CMV casesa 4 3 7 12 17 10 
Crude IRb 0.40 (0.01-0.78) 0.27 (0-0.57) 0.59 (0.15-1.02) 1.11 (0.48-1.73) 1.44 (0.76-2.12) 0.77 (0.29-1.24) 
Std. IRb 0.36 (0-0.89) 0.10 (0-0.22) 1.76 (0-3.8) 3.65 (0.54-6.76) 2.72 (0.65-4.79) 1.19 (0.27-2.10) 
Heart Total Pop. 69 92 103 117 112 141 
CMV casesa 2 3 2 6 5 8 
Crude IRb 2.90 (0-6.96) 3.26 (0-6.96) 1.94 (0-4.65) 5.13 (1.07-9.18) 4.46 (0.58-8.35) 5.67 (1.81-9.54) 
Std. IRb 2.12 (0-5.59) 5.94 (0-15.78) 1.32 (0-3.15) 4.87 (0-9.82) 3.16 (0.13-6.18) 5.78 (0.19-11.37) 
Lung Total Pop. 18 33 35 43 54 63 
CMV casesa 0 0 0 0 2 0 
Crude IRb — — — — 3.70 (0-8.91) — 
Std. IRb — — — — 8.30 (0-21.66) — 
Pancreas 
alone 
Total Pop. 25 39 35 60 54 59 
CMV casesa 1 1 1 0 3 1 
Crude IRb 4.00 (0-12.26) 2.56 (0-7.75) 2.86 (0-8.66) — 5.56 (0-11.87) 1.69 (0-5.09) 
Std. IRb 1.64 (0-4.84) 0.67 (0-1.99) 0.90 (0-2.65) — 6.99 (0-17.18) 0.52 (0-1.54) 
HSCT        
 Total Pop. 1,263 1,522 1,639 1,740 1,863 2,179 
 CMV casesa 4 2 7 5 11 16 
 Crude IRb 0.32 (0.01-0.63) 0.13 (0-0.31) 0.43 (0.11-0.74) 0.29 (0.04-0.54) 0.59 (0.24-0.94) 0.73 (0.38-1.09) 
 Std. IRb 0.35 (0-0.73) 0.10 (0-0.24) 0.36 (0.09-0.63) 0.27 (0.03-0.51) 0.49 (0.19-0.78) 0.70 (0.35-1.06) 
Whole population       
 Total Pop. 50,165,317 50,443,562 50,761,374 51,011,717 51,279,732 51,571,506 
 CMV casesa 159 206 205 259 359 398 
 Crude IRc 0.32 (0.27-0.37) 0.41 (0.35-0.46) 0.40 (0.35-0.46) 0.51 (0.45-0.57) 0.70 (0.63-0.77) 0.77 (0.70-0.85) 
 Std. IRc 0.32 (0.27-0.37) 0.41 (0.35-0.47) 0.40 (0.35-0.46) 0.50 (0.44-0.56) 0.68 (0.61-0.76) 0.75 (0.68-0.82) 
Data are expressed as number or IR (95% CI). aIndicate CMV disease except CMV syndrome. bPer 100 person-years. cPer 100,000 person-years. Crude IR means the 
unadjusted incidence rate. Standardized IRs are adjusted by age and sex using 2010 South Korea Population and Housing Census data. Aberrations: CI, confidence interval; 
CMV, cytomegalovirus; HSCT, hematopoietic stem cell transplantation; IR, incidence rate; Pop., population; SOT, solid organ transplantation, Std., standardized 
 
Table 2. Incidence rates of CMV disease except CMV syndrome in transplant recipients 
 Total number CMV casesa F/U duration (years) Unadjusted IR Adjusted IRb Adjusted HRb 
Whole population 50,165,317 1,586 45,494.48 0.005 (0.004-0.006) 0.006 (0.005-0.007) 1 (Reference) 
SOT 16,368 283 8124.10 33.7 (29.5-38.6) 33.1 (28.8-38.0) 5,517 (4,114-7,600)c 
 Kidney 9,381 192 4645.58 44.3 (37.9-51.9) 44.3 (37.7-52.1) 3.78 (2.54-5.85) 
 Liver 6,066 56 3024.34 11.5 (7.9-16.7) 11.1 (7.6-16.3) 1 (Reference) 
 Heart 502 25 246.06 107.4 (68.5-168.4) 104.2 (66.4-163.7) 8.60 (4.71-15.39) 
 Lung 168 2 83.78 18.2 (2.6-129.4) 17.3 (2.4-123.2) 1.30 (0.07-6.09) 
 Pancreas alone 68 2 33.87 47.7 (6.7-338.6) 52.9 (7.4-379.9) 3.51 (0.20-16.94) 
 Multi-organ 183 6 90.47 70.3 (29.3-169.0) 72.7 (30.2-175.4) 6.33 (2.13-15.24) 
HSCT 10,206 45 1291.82 9.0 (8.0-10.4) 5.1 (4.6-6.1) 850 (657-920)c 
Incidence rates are expressed as cases as per 1,000 person-years. aIndicate CMV disease except CMV syndrome. bAdjusted for age and sex. cComparison to the whole 
population. Aberrations: CMV, cytomegalovirus; F/U, follow up; HR, hazard ratio; IR, incidence rate 
 
Characteristics of patients with CMV case  
Among the 1,586 patients with CMV cases, 283 
(17.9%) and 45 (2.8%) patients received SOT and 
HSCT, respectively. A total of 1,258 (79.3%) patients 
had no transplantation history (neither SOT nor 
HSCT). The SOT recipients, HSCT recipients, and 
non-transplant groups had similar mean age, male 
percentage, and ICD-10 codes for CMV diagnosis 
(Table 3). According to transplant organs, the 
percentage of CMV among total recipients was 
highest in heart transplantation (25 CMV cases/502 
total recipients, 5.0%) followed by multi-organ (6/183, 
3.3%), pancreas (2/68, 2.9%), kidney (192/9,381, 
2.0%), lung (2/168, 1.2%), and liver transplantation 
(56/6,066, 0.9%) (Table 3, Figure 1, and 
Supplementary Table 1). The percentage of SOT 
recipients aged ≥ 40 years (68.9%) was significantly 
higher than that in HSCT recipients (55.6%) or 
non-transplant recipients (60.8%) (P = 0.026). The 
non-transplant population had the significantly 
higher rates of co-morbid diseases compared to SOT 
and HSCT recipients (P = 0.031). The 
post-transplantation duration before diagnosis of 




CMV cases was significantly shorter in HSCT 
recipients than in SOT recipients (2.2 ± 2.0 vs 3.4 ± 2.7 
months, P = 0.007) (Table 3). 
All-cause mortalities in patients with CMV 
cases 
 The percentage of all-cause death was 
significantly higher in HSCT recipients (28.9%) than 
in SOT recipients (6.4%) and non-transplant recipients 
(16.5%) (P < 0.001) (Table 3 and Figure 2). Cox’s 
proportional hazards regression analysis showed that 
SOT recipients had a significantly lower mortality rate 
(adjusted IR [95% CI] per 1,000 person-years, 53.2 
[33.4-84.8]; adjusted HR [95% CI], 0.4 [0.3-0.7] 
compared to that of non-transplant individuals with 
adjusted IR of 130 per 1,000 person-years). But, the 
adjusted mortality rate in the HSCT recipients (329.4 
[190.8-568.7] per 1.000 person-years) was significantly 
higher with the adjusted HR of 2.4 (1.3-4.0) compared 
to the non-transplant individuals (log-rank P < 0.001). 
Among transplant organs, only kidney transplan-
tation (33.4 [16.7-67.0] per 1,000 person-years) was 
associated with a significantly lower mortality rate 
(adjusted HR of 0.3 [0.1-0.5]) (Table 4). 
 
 
Table 3. Comparison of characteristics between solid organ, hematopoietic stem cell transplantation recipients, and non-transplant 
individuals among total 1,586 patients with CMV disease except CMV syndrome 
Characteristics No transplantation (N = 1,258) SOT (N = 283) HSCT (N = 45) P-value 
Age, years 42.1 ± 26.8 43.9 ± 17.0 40.9 ± 16.9 0.501 
  ≥ 40-year-old 765 (60.8) 195 (68.9) 25 (55.6) 0.026 
Sex, male 699 (55.6) 148 (52.3) 21 (46.7) 0.331 
Co-morbid illnessa 636 (50.6) 97 (34.3) 18 (40.0) 0.031 
  Type 2 DM 375 (29.8) 78 (27.6) 14 (31.1) 0.849 
  ESRD on dialysis 83 (6.6) 2 (0.7) 1 (2.2) 0.017 
 Chronic heart diseases 64 (5.1) 8 (2.8) 3 (6.7) 0.125 
 Chronic liver diseases 38 (3.0) 10 (3.5) 4 (8.9) 0.367 
 Chronic lung diseases 93 (7.4) 5 (1.8) 1 (2.2) 0.025 
 HIV-1 infection 20 (1.6) 0 (0) 0 (0) — 
Transplant organ    — 
  Single — 277 (97.9) —  
   Kidney — 192 (67.8) —  
   Liver — 56 (19.8) —  
   Heart — 25 (8.8) —  
   Lung — 2 (0.7) —  
   Pancreas alone — 2 (0.7) —  
  Multi-organ — 6 (2.1) —  
CMV diagnosisb    0.248 
  B25 3 (0.2) 0 (0) 0 (0)  
  B25.0 89 (7.1) 6 (2.1) 0 (0)  
  B25.1 101 (8.0) 4 (1.4) 0 (0)  
  B25.2 4 (0.3) 0 (0) 0 (0)  
  B25.8 465 (37.0) 80 (28.3) 20 (44.4)  
  B25.9 596 (47.4) 193 (68.2) 25 (55.6)  
Intervals between transplantation and CMV casesc, months — 3.4 ± 2.7 2.2 ± 2.0 0.007 
  Transplant organs     
   Kidney — 3.4 ± 2.7 —  
   Liver — 3.4 ± 2.8 —  
   Heart — 3.4 ± 2.5 —  
   Lung — 8.1 ± 3.0 —  
   Pancreas alone — 5.0 ± 0.8 —  
   Multi-organ — 2.9 ± 2.3 —  
 CMV diagnosisb      
  B25.0 — 6.2 ± 3.5 —  
  B25.1 — 2.0 ± 1.8 —  
  B25.8 — 3.9 ± 2.7 2.2 ± 1.2  
  B25.9 — 3.2 ± 2.6 2.3 ± 1.9  
All-cause death 207 (16.5) 18 (6.4) 13 (28.9) <0.001 
Data are expressed as mean ± standard deviation or number (percentage). aSome patients had several illnesses. bBy WHO ICD-10 codes, version 2016 (B25: cytomegaloviral 
disease, B25.0: cytomegaloviral pneumonitis, B25.1: cytomegaloviral hepatitis, B25.2: cytomegaloviral pancreatitis, B25.8: other cytomegaloviral diseases, B25.9: 
cytomegaloviral disease, unspecified). cIndicate CMV disease except CMV syndrome. Aberrations: CMV, cytomegalovirus; DM, diabetes mellitus; ESRD, end stage renal 
disease; HIV-1, human immunodeficiency virus-1; HSCT, hematopoietic stem cell transplantation; f/u, follow-up; ICD-10, International Statistical Classification of Diseases 
and Related-Health Problems 10th Revision; SOT, solid organ transplantation, WHO, World Health Organization 





Figure 2. All-cause mortality rates in solid organ transplantation recipients, hematopoietic stem cell transplantation recipients, and non-transplant individuals with CMV disease 
except CMV syndrome. *Log rank test. Aberrations: HSCT, hematopoietic stem cell transplantation; SOT, solid organ transplantation 
 
Table 4. All-cause mortality rates in solid organ transplantation recipients, hematopoietic stem cell transplantation recipients, and 
non-transplant individuals with CMV disease except CMV syndrome in Cox’s proportional hazards regression model 





IR (95% CI) HR (95% CI) IR (95% CI) HR (95% CI) 
Non-transplant individuals 1,258 207 1111.27 186.3 (162.6-213.5) 1 (Reference) 129.9 (107.5-156.8) 1 (Reference) 
SOT 283 18 271.45 66.3 (41.8-105.2) 0.37 (0.22-0.57) 53.2 (33.4-84.8) 0.42 (0.25-0.67) 
 Kidney 192 8 186.91 42.8 (21.4-85.6) 0.23 (0.10-0.43) 33.4 (16.7-67.0) 0.25 (0.11-0.48) 
 Liver 56 8 50.93 157.0 (78.6-314.1) 0.84 (0.38-1.58) 139.7 (69.6-280.4) 1.04 (0.47-1.98) 
 Heart 25 2 23.61 84.7 (21.2-338.7) 0.45 (0.08-1.40) 69.4 (17.3-277.8) 0.51 (0.09-1.60) 
 Lung 2 0 — — — — — 
 Pancreas alone 2 0 — — — — — 
 Multi-organ 6 0 — — — — — 
HSCT 45 13 36.91 352.2 (204.5-606.5) 1.81 (0.98-3.04) 329.4 (190.8-568.7) 2.37 (1.28-4.01) 
Incidence rates indicate cases as per 1,000 person-years. aAdjusted by age and sex using 2010 South Korea Population and Housing Census data. Aberrations: CI, confidence 




 The new finding in our data from a large entire 
population-based cohort was that the recipients with 
post-SOT CMV cases had lower (approximately 60% 
decrease) all-cause mortality rate than that of 
non-transplant individuals, although the SOT 
recipient group had a significantly higher IR (nearly 
5,000-fold) of CMV cases after transplantation 
compared to that of non-transplant individuals. The 
reduction in mortality rate was distinct in kidney 
transplant recipients (approximately 75% decrease). 
The comparison of IR or mortality of CMV cases in 
transplant recipients and non-transplant group has 
not been performed yet. Interestingly, the patients 
with CMV in each group were relatively young with a 
mean age of 40-44 years. This may be because 
non-transplant patients with various comorbidities 
may have a higher risk of adverse outcomes with 
CMV end-organ disease than SOT recipients, 
although post-SOT CMV disease could also be 
attributable to morbidity and mortality [30,31,49]. The 
relatively high all-cause mortality in individuals 
without transplantation might be related to the 
various co-morbid illnesses, especially ESRD on 
dialysis, chronic lung diseases, and HIV-1 infection, 
and/or the indirect effects of CMV disease, including 
the risk of infections by other bacteria or fungi 
[20,30,50]. 
Litjens et al. recently reported that donor- 
derived memory-like NKG2C+ natural killer cells and 
Vδ2negγδ T lymphocytes could be expanded by CMV 
replication, and the terminally differentiated TCR αβ+ 
T lymphocytes with poor alloimmunity, NKG2C gene 
expression, and resistance of the adaptive immune 
system driven by interferon could be enhanced 




during CMV infection [51]. These immunological 
alterations by active CMV replication may be 
associated with allograft acceptance in kidney, liver, 
or heart transplant recipients, as well as protection 
against post-HSCT leukemic relapse in patients with 
acute myeloid leukemia [27,51-57]. Even though 
further studies are needed to explore more evidence 
for causal relationships, some studies suggest that 
CMV infection or disease after transplantation might 
have beneficial effects to avoid various adverse 
morbidities or mortality in special recipients 
[51,58,59]. Our epidemiologic results might provide 
an opportunity to contemplate the large burden of 
CMV disease in non-transplant settings as well as the 
potential effect of CMV replication on a poor final 
outcome in transplant recipients with certain 
characteristics in actual clinical settings with CMV 
prevention strategies. 
In this analysis, the IR of CMV in the HSCT 
cohort did not differ considerably from that in the 
SOT recipients, which may be associated with proper 
prevention, especially in HSCT recipients with a 
generally higher risk of adverse effects caused by 
CMV reactivation. Unlike the prior reports on CMV 
risk factors, our SOT cohort had a relatively low IR for 
CMV in lung transplant recipients [30,31]. The IR for 
CMV in lung transplantation may be underestimated 
due to the exclusion of CMV syndrome in our study. 
However, all previous studies presenting CMV 
epidemiology with percentage did not assess IR, 
taking into consideration the follow-up duration 
[21-29,31]. This first analysis assessing direct 
comparison of CMV IRs according to transplant 
organs in a specific cohort showed that liver or lung 
transplant recipients had lower IRs for CMV, and 
heart transplant recipients had the highest IRs. The 
CMV cases in the kidney, liver, and heart transplant 
recipients occurred at a similar time after SOT (mean 
of 3.4 months). During the follow-up period, most 
CMV cases developed in the early post-trans-
plantation period in both SOT and HSCT recipients 
(mean of 3 and 2 months, respectively, and majority 
cases within 6 months) (Supplementary Figure 1A 
and 1B). 
This large cohort study is limited by the lack of 
information on CMV preventive strategies in the SOT 
and HSCT cohorts. Regardless of the consensus 
guidelines for CMV prevention in transplant settings, 
standardized protocols, including dosage or duration 
of anti-CMV drugs, strategies or surveillance of 
prevention (especially, application of recent hybrid 
approaches), cut-off thresholds of CMV viral load, 
monitoring methods for preemptive therapy, or 
management of refractory/recurrent/relapsed cases 
would be quite heterogeneous for each institution or 
physician [30,35,45,60]. This is because sophisticated 
strategies are based on tailored management in 
accordance with several risk factors and clinical 
conditions [30,45]. Unfortunately, it was not possible 
to extract detailed data on CMV preventive strategies 
from the national database, and this process revealed 
only a few CMV cases in various subgroups. 
Additionally, we could not evaluate the IRs of CMV 
according to the serostatus of donors and recipients, 
because almost all adult Koreans among general 
population and transplant recipients are seropositive 
for CMV [61-63]. The small number of CMV cases in 
the childhood and adolescent groups would assure 
the extraction of symptomatic CMV cases with the 
exclusion of congenital CMV infection, CMV 
mononucleosis, or asymptomatic CMV detection in 
the total cohort (Supplementary Tables 2 and 3). 
However, the absence of CMV syndrome in our 
dataset could underestimate the IR of CMV, especially 
in the transplant recipients. 
Nevertheless, our analysis is the first attempt to 
report the difference in IR and mortality between 
non-transplant individuals and SOT or HSCT 
recipients to assess the burden of CMV cases in 
clinical practice. Two previous cohort studies 
evaluated the association of CMV seropositivity with 
all-cause mortality in the adult general population 
without transplants, except in the pregnant women 
group. In 14,153 American adults, CMV seropositive 
rates were related to higher adjusted all-cause 
mortality (overall HR of 1.2) [42]. Another cohort of 
13,000 adults in the UK confirmed that CMV 
seropositive status (59% seroprevalence) was 
associated with increased all-cause mortality 
(adjusted HR of 1.2) [43]. However, these studies with 
small HRs did not compare mortality in intensively 
immunocompromised patients. Another strength of 
our study is that we did not use the seroprevalence 
rates or CMV IgG titers to identify the CMV group. 
Furthermore, our CMV cohort could exclude 
asymptomatic CMV detection in blood or body fluids. 
Conclusions  
Our large cohort from the entire 
population-based database showed that 
non-transplant individuals with CMV, regardless of 
low incidence of CMV disease, had higher all-cause 
mortality than SOT recipients. This finding suggests 
that active CMV replication causing CMV disease 
may be associated with a potentially large burden 
because of life-threatening outcomes in other patient 
groups besides severely immunocompromised 
transplant recipients.  
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